Study on clinical presentation of malaria and response to antimalarial treatment in children less than twelve years

Abstract

Background: In the tropical country of India, malaria in pediatric age group is one of the most important cause of mortality and morbidity. The study aimed to identify the clinicoepidemiologic features and response to antimalarial treatment in the children. Methods: Prospective analytical study conducted for the same over the period of two years in tertiary care hospital (September 2019 to September 2021). All children under twelve years hospitalised with fever and were diagnosed to have malaria by Peripheral smear or RDT were included in the study after ethical clearance and parental consent. Total sample size was 90. Results: Incidence of the malarial disease among total admitted patients in our study period was found to be 3.5%. The highest percentage of patients with malaria belonged to age group of 13m to 5 years (40%) and least being the age group 10-12years (7.7%). In study fever was found to be the major chief complaint followed by chills and rigor. Bleeding diathesis was least common It was found out from our study that overall most common clinical finding in the study patients was anemia or pallor with an overall of 35 patients (38.8%). Almost 73.3% (66) patients had anemia out of which 14.4% (13 patients) overall where found to have severe anemia and 27.7% (25) had moderate anemia and 31.1% (28 patients) had mild anemia. 27.7% (25) cases satisfied one or more WHO criteria for severe malaria. Conclusions: The emergence of severe malaria caused by P. vivax could have significant implications in planning the malaria-control programmes for the community. The widespread use of ACT for severe malaria as per the guidelines of the WHO could result in the emergence of resistant parasite strains. It may be rational to continue the use of chloroquine for malaria due to P. vivax in chloroquine-sensitive areas. In places where both P. vivax and P. falciparum co-exist, measures need to be equally targeted to P. vivax to decrease morbidity and mortality due to severe malaria.